Metabolomics for searching validated biomarkers in cancer studies: a decade in review

References

• Armitage EG, Ciborowski M. Applications of metabolomics in cancer studies. Adv Exp Med Biol. 2017;965:209–234. doi: 10.1007/978-3-319-47656-8_9 PubMed PMID: 28132182.
   PubMedGoogle Scholar
• fda.gov [internet]. Biomarker qualification: evidentiary framework. [ updated 2018 Dec; cited 2024 May 20]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biomarker-qualification-evidentiary-framework
   Google Scholar
• López-López Á, López-Gonzálvez Á, Barker-Tejeda TC, et al. A review of validated biomarkers obtained through metabolomics. Expert Rev Mol Diagn. 2018;18(6):557–575. Epub 2018/06/06. doi: 10.1080/14737159.2018.1481391 PubMed PMID: 29808702.
   PubMed Web of Science ®Google Scholar
• Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006;24(4):326–337. doi: 10.1016/j.urolonc.2005.11.023 PubMed PMID: 16818187.
   PubMed Web of Science ®Google Scholar
• Bansal N, Gupta A, Mitash N, et al. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J Proteome Res. 2013;12(12):5839–5850. doi: 10.1021/pr400859w PubMed PMID: WOS:000328231300043.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang M, Cheng X, et al. LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma. Front Oncol. 2020;10:717. Epub 20200515. doi: 10.3389/fonc.2020.00717 PubMed PMID: 32500026; PubMed Central PMCID: PMC7243740.
   PubMed Web of Science ®Google Scholar
• Tan GG, Wang HB, Yuan JL, et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Sci Rep. 2017;7(1):46176. doi: 10.1038/srep46176 PubMed PMID: WOS:000398592700001.
   PubMedGoogle Scholar
• Pasikanti KK, Esuvaranathan K, Hong Y, et al. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 2013;12(9):3865–3873. doi: 10.1021/pr4000448
   PubMed Web of Science ®Google Scholar
• Jin X, Yun SJ, Jeong P, et al. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget. 2014;5(6):1635. doi: 10.18632/oncotarget.1744
   PubMedGoogle Scholar
• Wittmann BM, Stirdivant SM, Mitchell MW, et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLOS ONE. 2014;9(12):e115870. doi: 10.1371/journal.pone.0115870
   PubMed Web of Science ®Google Scholar
• Zhou Y, Song RX, Ma C, et al. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method. Oncotarget. 2017;8(13):20719–20728. doi: 10.18632/oncotarget.14988 PubMed PMID: WOS:000397642400020.
   PubMedGoogle Scholar
• Liu X, Cheng X, He L, et al. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. Int J Cancer. 2018;143(2):408–418. Epub 20180302. doi: 10.1002/ijc.31323 PubMed PMID: 29451296.
   PubMed Web of Science ®Google Scholar
• Cheng X, Liu X, Guo Z, et al. Metabolomics of non-muscle invasive bladder cancer: biomarkers for early detection of bladder cancer. Front Oncol. 2018;8:494. Epub 20181102. doi: 10.3389/fonc.2018.00494 PubMed PMID: 30450336; PubMed Central PMCID: PMC6224486.
   PubMed Web of Science ®Google Scholar
• Lin J-Y, Juo B-R, Yeh Y-H, et al. Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics. BMC Bioinformatics. 2021;22(1). doi: 10.1186/s12859-021-04235-z
   Web of Science ®Google Scholar
• Oto J, Fernández-Pardo Á, Roca M, et al. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer. World J Urol. 2022;40(10):2387–2398. Epub 20220904. doi: 10.1007/s00345-022-04136-7 PubMed PMID: 36057894.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu X, Sun H, et al. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. BMC Cancer. 2019;19(1):1195. Epub 20191205. doi: 10.1186/s12885-019-6354-1 PubMed PMID: 31805976; PubMed Central PMCID: PMC6896793.
   PubMed Web of Science ®Google Scholar
• Yatsuoka W, Ueno T, Miyano K, et al. Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw. PLOS ONE. 2019;14(8):e0220712. Epub 20190812. doi: 10.1371/journal.pone.0220712 PubMed PMID: 31404085; PubMed Central PMCID: PMC6690531.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461. Epub 20140225. doi: 10.1002/cncr.28592 PubMed PMID: 24615748; PubMed Central PMCID: PMC4164022.
   PubMed Web of Science ®Google Scholar
• Yang QJ, Zhao JR, Hao J, et al. Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. J Cachexia Sarcopenia Muscle. 2018;9(1):71–85. doi: 10.1002/jcsm.12246
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Chou J, et al. Taurine, glutamic acid and ethylmalonic acid as important metabolites for detecting human breast cancer based on the targeted metabolomics. Cancer Biomark. 2018;23(2):255–268. doi: 10.3233/cbm-181500 PubMed PMID: 30103303.
   PubMed Web of Science ®Google Scholar
• Park J, Shin Y, Kim TH, et al. Plasma metabolites as possible biomarkers for diagnosis of breast cancer. PLOS ONE. 2019;14(12):e0225129. Epub 20191203. doi: 10.1371/journal.pone.0225129 PubMed PMID: 31794572; PubMed Central PMCID: PMC6890236.
   PubMed Web of Science ®Google Scholar
• Zhao H, Shen J, Moore SC, et al. Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019;176(3):687–696. Epub 20190215. doi: 10.1007/s10549-019-05165-4 PubMed PMID: 30771047; PubMed Central PMCID: PMC6588417.
   PubMed Web of Science ®Google Scholar
• Yuan B, Schafferer S, Tang Q, et al. A plasma metabolite panel as biomarkers for early primary breast cancer detection. Int J Cancer. 2019;144(11):2833–2842. Epub 20190104. doi: 10.1002/ijc.31996 PubMed PMID: 30426507.
   PubMed Web of Science ®Google Scholar
• Tomida S, Goodenowe DB, Koyama T, et al. Plasmalogen deficiency and overactive fatty acid elongation biomarkers in serum of breast cancer patients pre- and post-surgery—new insights on diagnosis, risk assessment, and disease mechanisms. Cancers (Basel). 2021;13(16). Epub 20210819. doi: 10.3390/cancers13164170 PubMed PMID: 34439324; PubMed Central PMCID: PMC8391794.
   PubMed Web of Science ®Google Scholar
• Khan I, Nam M, Kwon M, et al. LC/MS-based polar metabolite profiling identified unique biomarker signatures for cervical cancer and cervical intraepithelial neoplasia using global and targeted metabolomics. Cancers (Basel). 2019;11(4). Epub 20190410. doi: 10.3390/cancers11040511 PubMed PMID: 30974861; PubMed Central PMCID: PMC6521312.
   Web of Science ®Google Scholar
• Cheng F, Wen Z, Feng X, et al. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer. Life Sci. 2020;260:118489. Epub 20200923. doi: 10.1016/j.lfs.2020.118489 PubMed PMID: 32976882.
   PubMed Web of Science ®Google Scholar
• Liang Q, Liu H, Zhang TY, et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. Mol Biosyst. 2016;12(2):334–340. doi: 10.1039/c5mb00572h PubMed PMID: WOS:000368858900002.
   PubMed Web of Science ®Google Scholar
• Macias RIR, Muñoz-Bellvís L, Sánchez-Martín A, et al. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(6):1433. Epub 20200531. doi: 10.3390/cancers12061433 PubMed PMID: 32486461; PubMed Central PMCID: PMC7352809.
   PubMed Web of Science ®Google Scholar
• Yang B, Wang C, Xie Y, et al. Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients. Cancer Sci. 2018;109(3):777–784. Epub 2018/02/14. doi: 10.1111/cas.13500 PubMed PMID: 29316075; PubMed Central PMCID: PMC5834806.
   PubMed Web of Science ®Google Scholar
• Brown AL, Sok P, Taylor O, et al. Cerebrospinal fluid metabolomic profiles associated with fatigue during treatment for pediatric acute lymphoblastic leukemia. J Pain Symptom Manage. 2021;61(3):464–473. Epub 20200901. doi: 10.1016/j.jpainsymman.2020.08.030 PubMed PMID: 32889041; PubMed Central PMCID: PMC7914130.
   PubMed Web of Science ®Google Scholar
• Udo R, Katsumata K, Kuwabara H, et al. Urinary charged metabolite profiling of colorectal cancer using capillary electrophoresis-mass spectrometry. Sci Rep. 2020;10(1):21057. Epub 20201203. doi: 10.1038/s41598-020-78038-2 PubMed PMID: 33273632; PubMed Central PMCID: PMC7713069.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Katsumata K, Udo R, et al. Validation of urinary charged metabolite profiles in colorectal cancer using capillary electrophoresis-mass spectrometry. Metabolites. 2022;12(1):59. Epub 20220110. doi: 10.3390/metabo12010059 PubMed PMID: 35050180; PubMed Central PMCID: PMC8779129.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li C, Deng K, et al. Metabolic phenotyping to monitor chronic enteritis canceration. Metabolomics. 2020;16(3):29. Epub 20200224. doi: 10.1007/s11306-020-1651-x PubMed PMID: 32095917.
   PubMed Web of Science ®Google Scholar
• Rattner JI, Kopciuk KA, Vogel HJ, et al. Early detection of treatment futility in patients with metastatic colorectal cancer. Oncotarget. 2022;13:61–72. Epub 20220107. doi: 10.18632/oncotarget.28165 PubMed PMID: 35028011; PubMed Central PMCID: PMC8746015.
   PubMedGoogle Scholar
• Crotti S, Agnoletto E, Cancemi G, et al. Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. Anal Bioanal Chem. 2016;408(23):6321–6328. doi: 10.1007/s00216-016-9743-1
   PubMed Web of Science ®Google Scholar
• Zha H, Cai Y, Yin Y, et al. SWATHtoMRM: development of high-coverage targeted metabolomics method using swath technology for biomarker discovery. Anal Chem. 2018;90(6):4062–4070. Epub 20180302. doi: 10.1021/acs.analchem.7b05318 PubMed PMID: 29485856.
   PubMed Web of Science ®Google Scholar
• Lin Y, Ma C, Bezabeh T, et al. (1) H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples. Int J Cancer. 2019;145(6):1679–1689. Epub 20190304. doi: 10.1002/ijc.32190 PubMed PMID: 30720869.
   PubMed Web of Science ®Google Scholar
• Ecker J, Benedetti E, Kindt ASD, et al. The colorectal cancer lipidome: identification of a robust tumor-specific lipid species signature. Gastroenterology. 2021;161(3):910–23.e19. Epub 20210515. doi: 10.1053/j.gastro.2021.05.009 PubMed PMID: 34000281.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Kopciuk KA, Hilsden R, et al. A quantitative multimodal metabolomic assay for colorectal cancer. BMC Cancer. 2018;18(26). doi: 10.1186/s12885-017-3923-z PubMed PMID: WOS:000419225200008.
   PubMedGoogle Scholar
• Chen F, Dai X, Zhou CC, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022;71(7):1315–1325. Epub 20210830. doi: 10.1136/gutjnl-2020-323476 PubMed PMID: 34462336; PubMed Central PMCID: PMC9185821.
   PubMed Web of Science ®Google Scholar
• Tevini J, Eder SK, Huber-Schönauer U, et al. Changing metabolic patterns along the colorectal adenoma–carcinoma sequence. J Clin Med. 2022;11(3):721. PubMed PMID doi:10.3390/jcm11030721
   PubMed Web of Science ®Google Scholar
• Bian X, Qian Y, Tan B, et al. In-depth mapping carboxylic acid metabolome reveals the potential biomarkers in colorectal cancer through characteristic fragment ions and metabolic flux. Anal Chim Acta. 2020;1128:62–71. Epub 20200711. doi: 10.1016/j.aca.2020.06.064 PubMed PMID: 32825913.
   PubMed Web of Science ®Google Scholar
• Del Boccio P, Perrotti F, Rossi C, et al. Serum lipidomic study reveals potential early biomarkers for predicting response to chemoradiation therapy in advanced rectal cancer: a pilot study. Adv Radiat Oncol. 2017;2(2):118–124. Epub 20170105. doi: 10.1016/j.adro.2016.12.005 PubMed PMID: 28740922; PubMed Central PMCID: PMC5514249.
   PubMedGoogle Scholar
• Bahado-Singh RO, Lugade A, Field J, et al. Metabolomic prediction of endometrial cancer. Metabolomics. 2018;14(6). doi: 10.1007/s11306-017-1290-z PubMed PMID: WOS:000424713300001.
   Google Scholar
• Troisi J, Sarno L, Landolfi A, et al. A metabolomic signature of endometrial cancer. J Proteome Res. 2018;17(2):804–812. doi: 10.1021/acs.jproteome.7b00503
   PubMed Web of Science ®Google Scholar
• Yan X, Zhao W, Wei J, et al. A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia. Int J Cancer. 2022;150(9):1549–1559. Epub 20220210. doi: 10.1002/ijc.33943 PubMed PMID: 35076938.
   PubMed Web of Science ®Google Scholar
• Cheng SC, Chen K, Chiu CY, et al. Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy. Metabolomics. 2019;15(11):146. Epub 20191029. doi: 10.1007/s11306-019-1609-z PubMed PMID: 31664624.
   PubMed Web of Science ®Google Scholar
• Yin R, Yang T, Su H, et al. Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis. Cancer Biomarkers. 2016;17(3):259–269. doi: 10.3233/CBM-160638
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Zhao J, et al. Serum metabolite signatures of epithelial ovarian cancer based on targeted metabolomics. Clin Chim Acta. 2021;518:59–69. Epub 20210318. doi: 10.1016/j.cca.2021.03.012 PubMed PMID: 33746017.
   PubMed Web of Science ®Google Scholar
• Yang W, Mu T, Jiang J, et al. Identification of potential biomarkers and metabolic profiling of serum in ovarian cancer patients using UPLC/Q-TOF MS. Cell Physiol Biochem. 2018;51(3):1134–1148. Epub 20181126. doi: 10.1159/000495492 PubMed PMID: 30476914.
   PubMedGoogle Scholar
• Braicu EI, Darb-Esfahani S, Schmitt WD, et al. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget. 2017;8(61):102912–102922. Epub 20171026. doi: 10.18632/oncotarget.22076 PubMed PMID: 29262533; PubMed Central PMCID: PMC5732699.
   PubMedGoogle Scholar
• Niemi RJ, Braicu EI, Kulbe H, et al. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018;119(7):847–854. Epub 20181008. doi: 10.1038/s41416-018-0270-z PubMed PMID: 30293997; PubMed Central PMCID: PMC6189177.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Liang D, Ajani JA, et al. Identification of serum markers of esophageal adenocarcinoma by global and targeted metabolic profiling. Clin Gastroenterol Hepatol. 2015;13(10):1730–7. e9. doi: 10.1016/j.cgh.2015.05.023
   PubMed Web of Science ®Google Scholar
• Ye W, Lin Y, Bezabeh T, et al. (1) H NMR-based metabolomics of paired esophageal tumor tissues and serum samples identifies specific serum biomarkers for esophageal cancer. NMR Biomed. 2021;34(6):e4505. Epub 20210330. doi: 10.1002/nbm.4505 PubMed PMID: 33783927.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang C, Zhang M, et al. Angustoline inhibited esophageal tumors through regulating LKB1/AMPK/ELAVL1/LPACT2 pathway and phospholipid remodeling. Front Oncol. 2020;10:1094. Epub 20200707. doi: 10.3389/fonc.2020.01094 PubMed PMID: 32733803; PubMed Central PMCID: PMC7358378.
   PubMed Web of Science ®Google Scholar
• Zhang S, Lu X, Hu C, et al. Serum metabolomics for biomarker screening of esophageal squamous cell carcinoma and esophageal squamous dysplasia using gas chromatography-mass spectrometry. ACS Omega. 2020;5(41):26402–26412. Epub 20201012. doi: 10.1021/acsomega.0c02600 PubMed PMID: 33110968; PubMed Central PMCID: PMC7581083.
   PubMed Web of Science ®Google Scholar
• Wang JL, Zhang T, Shen XT, et al. Serum metabolomics for early diagnosis of esophageal squamous cell carcinoma by UHPLC-QTOF/MS. Metabolomics. 2016;12:116. doi: 10.1007/s11306-016-1050-5 PubMed PMID: WOS:000379508500008.
   Web of Science ®Google Scholar
• Zhu ZJ, Qi Z, Zhang J, et al. Untargeted metabolomics analysis of esophageal squamous cell carcinoma discovers dysregulated metabolic pathways and potential diagnostic biomarkers. J Cancer. 2020;11(13):3944–3954. Epub 20200406. doi: 10.7150/jca.41733 PubMed PMID: 32328198; PubMed Central PMCID: PMC7171502.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhao Z, Xue L, et al. Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning. Br J Cancer. 2021;125(3):351–357. Epub 20210505. doi: 10.1038/s41416-021-01395-w PubMed PMID: 33953345; PubMed Central PMCID: PMC8329198.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen Y, Zhang R, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol Cell Proteomics. 2013;12(5):1306–1318. doi: 10.1074/mcp.M112.022830 PubMed PMID: WOS:000319705100022.
   PubMed Web of Science ®Google Scholar
• Chen Z, Gao Y, Huang X, et al. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma. J Pharm Biomed Anal. 2021;197:113937. Epub 20210205. doi: 10.1016/j.jpba.2021.113937 PubMed PMID: 33609949.
   PubMed Web of Science ®Google Scholar
• Huang R, Shen K, He Q, et al. Metabolic profiling of urinary chiral amino-containing biomarkers for gastric cancer using a sensitive chiral chlorine-labeled probe by HPLC-MS/MS. J Proteome Res. 2021;20(8):3952–3962. Epub 20210706. doi: 10.1021/acs.jproteome.1c00267 PubMed PMID: 34229439.
   PubMed Web of Science ®Google Scholar
• Chen YN, Zhang J, Guo L, et al. A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis. Oncotarget. 2016;7(52):87496–87510. doi: 10.18632/oncotarget.11754 PubMed PMID: WOS:000391422500146.
   PubMedGoogle Scholar
• Jung J, Jung Y, Bang EJ, et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using nmr-based metabolomic profiling. Ann Surg Oncol. 2014;21(S4):S736–S742. doi: 10.1245/s10434-014-3886-0 PubMed PMID: WOS:000345320300043.
   PubMedGoogle Scholar
• Huang S, Guo Y, Li Z-W, et al. Identification and validation of plasma metabolomic signatures in precancerous gastric lesions that progress to cancer. JAMA Netw Open. 2021;4(6):e2114186. doi: 10.1001/jamanetworkopen.2021.14186
   PubMed Web of Science ®Google Scholar
• Liu ZC, Wu WH, Huang S, et al. Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study. Theranostics. 2022;12(10):4671–4683. Epub 20220606. doi: 10.7150/thno.74770 PubMed PMID: 35832080; PubMed Central PMCID: PMC9254242.
   PubMed Web of Science ®Google Scholar
• Corona G, Cannizzaro R, Miolo G, et al. Use of metabolomics as a complementary omic approach to implement risk criteria for first-degree relatives of gastric cancer patients. Int J Mol Sci. 2018;19(3):750. Epub 20180307. doi: 10.3390/ijms19030750 PubMed PMID: 29518896; PubMed Central PMCID: PMC5877611.
   PubMed Web of Science ®Google Scholar
• Wang D, Li W, Yin L, et al. Association of serum levels of deoxyribose 1-phosphate and S-lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: a metabolomics study. Oncol Lett. 2020;19(3):2231–2242. Epub 20200124. doi: 10.3892/ol.2020.11350 PubMed PMID: 32194721; PubMed Central PMCID: PMC7039117.
   PubMed Web of Science ®Google Scholar
• Han Y, Yoo HJ, Jee SH, et al. High serum levels of L-carnitine and citric acid negatively correlated with alkaline phosphatase are detectable in Koreans before gastric cancer onset. Metabolomics. 2022;18(8):62. Epub 20220728. doi: 10.1007/s11306-022-01922-7 PubMed PMID: 35900644.
   PubMed Web of Science ®Google Scholar
• Zhao H, Heimberger AB, Lu ZM, et al. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016;7(15):20486–20495. doi: 10.18632/oncotarget.7974 PubMed PMID: WOS:000375804000105.
   PubMedGoogle Scholar
• Jonsson P, Antti H, Späth F, et al. Identification of pre-diagnostic metabolic patterns for glioma using subset analysis of matched repeated time points. Cancers (Basel). 2020;12(11):3349. Epub 20201112. doi: 10.3390/cancers12113349 PubMed PMID: 33198241; PubMed Central PMCID: PMC7696703.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ji N, Wang G, et al. Metabolic detection of malignant brain gliomas through plasma lipidomic analysis and support vector machine-based machine learning. EBioMedicine. 2022;81:104097. Epub 20220607. doi: 10.1016/j.ebiom.2022.104097 PubMed PMID: 35687958; PubMed Central PMCID: PMC9189781.
   PubMed Web of Science ®Google Scholar
• Gao R, Cheng J, Fan C, et al. Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. Sci Rep. 2015;5(1):18175. doi: 10.1038/srep18175
   PubMedGoogle Scholar
• Kim DJ, Cho EJ, Yu KS, et al. Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers (Basel). 2019;11(10):1497. Epub 20191006. doi: 10.3390/cancers11101497 PubMed PMID: 31590436; PubMed Central PMCID: PMC6826937.
   PubMed Web of Science ®Google Scholar
• Zeng J, Yin PY, Tan YX, et al. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis–mass spectrometry. J Proteome Res. 2014;13(7):3420–3431. doi: 10.1021/pr500390y PubMed PMID: WOS:000338693400026.
   PubMed Web of Science ®Google Scholar
• Lu YH, Li N, Gao L, et al. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma. Cancer Res. 2016;76(10):2912–2920. doi: 10.1158/0008-5472.can-15-3199 PubMed PMID: WOS:000375841000010.
   PubMed Web of Science ®Google Scholar
• Zeng J, Huang X, Zhou LN, et al. Metabolomics identifies biomarker pattern for early diagnosis of hepatocellular carcinoma: from diethylnitrosamine treated rats to patients. Sci Rep. 2015;5(1):16101. doi: 10.1038/srep16101 PubMed PMID: WOS:000363950300001.
   PubMedGoogle Scholar
• Chen T, Zhou K, Sun T, et al. Altered bile acid glycine: taurine ratio in the progression of chronic liver disease. J Gastroenterol Hepatol. 2022;37(1):208–215. doi: 10.1111/jgh.15709
   PubMed Web of Science ®Google Scholar
• Cao LL, Han Y, Wang Y, et al. Metabolic profiling identified a novel biomarker panel for metabolic syndrome-positive hepatocellular cancer. Front Endocrinol. 2021;12:816748. Epub 20220126. doi: 10.3389/fendo.2021.816748 PubMed PMID: 35154012; PubMed Central PMCID: PMC8826723.
   PubMed Web of Science ®Google Scholar
• Luo P, Yin P, Hua R, et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018;67(2):662–675. doi: 10.1002/hep.29561 PubMed PMID: MEDLINE:28960374.
   PubMed Web of Science ®Google Scholar
• Huang Q, Tan YX, Yin PY, et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013;73(16):4992–5002. doi: 10.1158/0008-5472.can-13-0308 PubMed PMID: WOS:000323161800005.
   PubMed Web of Science ®Google Scholar
• Han J, Han ML, Xing H, et al. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer. 2020;146(6):1741–1753. Epub 20190813. doi: 10.1002/ijc.32599 PubMed PMID: 31361910.
   PubMed Web of Science ®Google Scholar
• Shao Y, Zhu B, Zheng R, et al. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. J Proteome Res. 2014;14(2):906–916. doi: 10.1021/pr500973d
   PubMed Web of Science ®Google Scholar
• Sun J, Zhao Y, Qin L, et al. Metabolomic profiles for HBV related hepatocellular carcinoma including alpha-fetoproteins positive and negative subtypes. Front Oncol. 2019;9:1069. Epub 20191015. doi: 10.3389/fonc.2019.01069 PubMed PMID: 31681602; PubMed Central PMCID: PMC6803550.
   PubMed Web of Science ®Google Scholar
• Zhao C, Kong X, Han S, et al. Analysis of differential metabolites in lung cancer patients based on metabolomics and bioinformatics. Future Oncol. 2020;16(18):1269–1287. Epub 20200501. doi: 10.2217/fon-2019-0818 PubMed PMID: 32356461.
   PubMed Web of Science ®Google Scholar
• Li YJ, Song X, Zhao XJ, et al. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B-Analytical Technol Biomed Life Sci. 2014;966:147–153. doi: 10.1016/j.jchromb.2014.04.047 PubMed PMID: WOS:000340323200018.
   PubMed Web of Science ®Google Scholar
• Wen C-P, Zhang F, Liang D, et al. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res. 2015;21(1):193–200. doi: 10.1158/1078-0432.ccr-14-0748 PubMed PMID: WOS:000347462600024.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wang Z, Liu X, et al. Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling. Clin Cancer Res. 2018;24(9):2100–2109. Epub 20180206. doi: 10.1158/1078-0432.ccr-17-2855 PubMed PMID: 29437793.
   PubMed Web of Science ®Google Scholar
• Peng F, Liu Y, He C, et al. Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC–MS metabolomics approach. J Pharm Biomed Anal. 2018;154:95–101. doi: 10.1016/j.jpba.2018.02.051
   PubMed Web of Science ®Google Scholar
• Nie X, Xia L, Gao F, et al. Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer. Front Mol Biosci. 2021;8:678753. Epub 20210521. doi: 10.3389/fmolb.2021.678753 PubMed PMID: 34095230; PubMed Central PMCID: PMC8176105.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Hanash S, DeFelice B, et al. Diacetylspermine is a novel prediagnostic serum biomarker for non–small-cell lung cancer and has additive performance with pro-surfactant protein B. J Clin Oncol. 2015;33(33):3880–3886. doi: 10.1200/JCO.2015.61.7779
   PubMed Web of Science ®Google Scholar
• Chen Y, Ma Z, Zhong J, et al. Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer. Sci Rep. 2018;8(1):7137. Epub 20180508. doi: 10.1038/s41598-018-25552-z PubMed PMID: 29740076; PubMed Central PMCID: PMC5940703.
   PubMed Web of Science ®Google Scholar
• Mu Y, Zhou Y, Wang Y, et al. Serum metabolomics study of nonsmoking female patients with non-small cell lung cancer using gas chromatography-mass spectrometry. J Proteome Res. 2019;18(5):2175–2184. Epub 20190329. doi: 10.1021/acs.jproteome.9b00069 PubMed PMID: 30892048.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ma Z, Shen X, et al. Serum lipidomics profiling to identify biomarkers for non-small cell lung cancer. Biomed Res Int. 2018;2018:5276240. Epub 20180807. doi: 10.1155/2018/5276240 PubMed PMID: 30175133; PubMed Central PMCID: PMC6106807.
   PubMed Web of Science ®Google Scholar
• Ruiying C, Zeyun L, Yongliang Y, et al. A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer. PLoS One. 2020;15(5):e0232272. Epub 20200506. doi: 10.1371/journal.pone.0232272 PubMed PMID: 32374740; PubMed Central PMCID: PMC7202610.
   PubMed Web of Science ®Google Scholar
• Shen J, Ye YQ, Chang DW, et al. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Lung Cancer. 2017;114:70–78. doi: 10.1016/j.lungcan.2017.10.018 PubMed PMID: WOS:000418782300012.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zheng J, Ahmed R, et al. A high-performing plasma metabolite panel for early-stage lung cancer detection. Cancers (Basel). 2020;12(3):622. Epub 20200307. doi: 10.3390/cancers12030622 PubMed PMID: 32156060; PubMed Central PMCID: PMC7139410.
   PubMed Web of Science ®Google Scholar
• Yu Z, Chen H, Ai J, et al. Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer. Oncotarget. 2017;8(64):107899–107906. Epub 20171111. doi: 10.18632/oncotarget.22391 PubMed PMID: 29296211; PubMed Central PMCID: PMC5746113.
   PubMedGoogle Scholar
• Xiang C, Jin S, Zhang J, et al. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer. Int J Biol Markers. 2018;33(3):314–320. Epub 20180613. doi: 10.1177/1724600818778754 PubMed PMID: 29896992.
   PubMed Web of Science ®Google Scholar
• Yu L, Li K, Li X, et al. Metabolomic profiling of dried blood spots reveals gender-specific discriminant models for the diagnosis of small cell lung cancer. Aging (Albany NY). 2020;12(1):978–995. Epub 20200112. doi: 10.18632/aging.102670 PubMed PMID: 31929115; PubMed Central PMCID: PMC6977651.
   PubMedGoogle Scholar
• Miller HA, Yin X, Smith SA, et al. Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data. Lung Cancer. 2021;156:20–30. Epub 20210415. doi: 10.1016/j.lungcan.2021.04.012 PubMed PMID: 33882406; PubMed Central PMCID: PMC8138715.
   PubMed Web of Science ®Google Scholar
• Soldevilla B, López-López A, Lens-Pardo A, et al. Comprehensive plasma metabolomic profile of patients with advanced neuroendocrine tumors (NETs). Diagnostic Biol Relevance Cancers. 2021;13(11):2634. PubMed PMID doi:10.3390/cancers13112634
   Google Scholar
• Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87(1):14–32. doi: 10.1177/154405910808700104 PubMed PMID: 18096889.
   PubMed Web of Science ®Google Scholar
• Ye GZ, Liu Y, Yin PY, et al. Study of induction chemotherapy efficacy in oral squamous cell carcinoma using pseudotargeted metabolomics. J Proteome Res. 2014;13(4):1994–2004. doi: 10.1021/pr4011298 PubMed PMID: WOS:000334016400020.
   PubMed Web of Science ®Google Scholar
• Lohavanichbutr P, Zhang Y, Wang P, et al. Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls. PLOS ONE. 2018;13(9):e0204249. Epub 20180920. doi: 10.1371/journal.pone.0204249 PubMed PMID: 30235319; PubMed Central PMCID: PMC6147497.
   PubMed Web of Science ®Google Scholar
• Bednarczyk K, Gawin M, Chekan M, et al. Discrimination of normal oral mucosa from oral cancer by mass spectrometry imaging of proteins and lipids. J Mol Histol. 2019;50(1):1–10. Epub 20181103. doi: 10.1007/s10735-018-9802-3 PubMed PMID: 30390197; PubMed Central PMCID: PMC6323087.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Nishiumi S, Ikeda A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):571–579. doi: 10.1158/1055-9965.epi-12-1033 PubMed PMID: WOS:000317960900013.
   PubMed Web of Science ®Google Scholar
• Jiao L, Maity S, Coarfa C, et al. A prospective targeted serum metabolomics study of pancreatic cancer in postmenopausal women. Cancer Prev Res (Phila). 2019;12(4):237–246. Epub 20190205. doi: 10.1158/1940-6207.capr-18-0201 PubMed PMID: 30723176; PubMed Central PMCID: PMC6445762.
   PubMed Web of Science ®Google Scholar
• Wang S, Li M, Yan L, et al. Metabolomics study reveals systematic metabolic dysregulation and early detection markers associated with incident pancreatic cancer. Int J Cancer. 2022;150(7):1091–1100. doi: 10.1002/ijc.33877
   PubMed Web of Science ®Google Scholar
• Fukutake N, Ueno M, Hiraoka N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLOS ONE. 2015;10(7):e0132223. doi: 10.1371/journal.pone.0132223 PubMed PMID: WOS:000358154400107.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Kobayashi T, Nishiumi S, et al. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clinica Chimica Acta. 2017;468:98–104. doi: 10.1016/j.cca.2017.02.011 PubMed PMID: WOS:000403121800017.
   PubMed Web of Science ®Google Scholar
• Tao L, Zhou J, Yuan C, et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabolomics. 2019;15(6):86. Epub 20190530. doi: 10.1007/s11306-019-1550-1 PubMed PMID: 31147790.
   PubMed Web of Science ®Google Scholar
• Luo X, Liu J, Wang H, et al. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacol Res. 2020;156:104805. Epub 20200408. doi: 10.1016/j.phrs.2020.104805 PubMed PMID: 32278036.
   PubMed Web of Science ®Google Scholar
• Sahni S, Pandya AR, Hadden WJ, et al. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Int J Cancer. 2021;148(6):1508–1518. Epub 20201112. doi: 10.1002/ijc.33368 PubMed PMID: 33128797.
   PubMed Web of Science ®Google Scholar
• Hipperson L, Hadden WJ, Nahm CB, et al. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas. Biochim Biophys Acta Gen Subj. 2021;1865(11):129966. Epub 20210727. doi: 10.1016/j.bbagen.2021.129966 PubMed PMID: 34329704.
   PubMed Web of Science ®Google Scholar
• Fahrmann JF, Bantis LE, Capello M, et al. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. J Natl Cancer Inst. 2019;111(4):372–379. doi: 10.1093/jnci/djy126 PubMed PMID: 30137376; PubMed Central PMCID: PMC6449169.
   PubMedGoogle Scholar
• Zhang X, Shi X, Lu X, et al. Novel metabolomics serum biomarkers for pancreatic ductal adenocarcinoma by the comparison of pre-, postoperative and normal samples. J Cancer. 2020;11(16):4641–4651. doi: 10.7150/jca.41250
   PubMed Web of Science ®Google Scholar
• Lindahl A, Heuchel R, Forshed J, et al. Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics. Metabolomics. 2017;13:61. doi: 10.1007/s11306-017-1199-6 PubMed PMID: WOS:000399681400016.
   PubMed Web of Science ®Google Scholar
• Mayerle J, Kalthoff H, Reszka R, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018;67(1):128–137. doi: 10.1136/gutjnl-2016-312432
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhao R, Guo K, et al. Potential metabolite biomarkers for early detection of stage-i pancreatic ductal adenocarcinoma. Front Oncol. 2021;11:744667. Epub 20220119. doi: 10.3389/fonc.2021.744667 PubMed PMID: 35127469; PubMed Central PMCID: PMC8807510.
   PubMed Web of Science ®Google Scholar
• Zhao R, Ren S, Li C, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Med. 2023;12(4):5158–5171. Epub 20220926. doi: 10.1002/cam4.5296 PubMed PMID: 36161527; PubMed Central PMCID: PMC9972159.
   PubMed Web of Science ®Google Scholar
• Guo S, Qiu L, Wang YM, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal Bioanal Chem. 2014;406(18):4357–4370. doi: 10.1007/s00216-014-7846-0 PubMed PMID: WOS:000338722400005.
   PubMed Web of Science ®Google Scholar
• Huang FQ, Li J, Jiang L, et al. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma. Int J Cancer. 2019;144(4):868–876. Epub 20181203. doi: 10.1002/ijc.31925 PubMed PMID: 30318614.
   PubMed Web of Science ®Google Scholar
• Chen J, Hu Q, Hou H, et al. Metabolite analysis-aided diagnosis of papillary thyroid cancer. Endocr Relat Cancer. 2019;26(12):829–841. doi: 10.1530/erc-19-0344 PubMed PMID: 31671400.
   PubMed Web of Science ®Google Scholar
• Lima AR, Bastos MD, Carvalho M, et al. Biomarker discovery in human prostate cancer: an update in metabolomics studies. Transl Oncol. 2016;9(4):357–370. doi: 10.1016/j.tranon.2016.05.004 PubMed PMID: WOS:000386772100013.
   PubMed Web of Science ®Google Scholar
• Kiebish MA, Cullen J, Mishra P, et al. Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer. J Transl Med. 2020;18(1):10. Epub 20200107. doi: 10.1186/s12967-019-02185-y. PubMed PMID: 31910880; PubMed Central PMCID: PMC6945688. doi: 10.1186/s12967-019-02185-y
   PubMed Web of Science ®Google Scholar
• Xu H, Chen J, He J, et al. Serum metabolic profiling identifies a biomarker panel for improvement of prostate cancer diagnosis. Front Oncol. 2021;11:666320. Epub 20210507. doi: 10.3389/fonc.2021.666320 PubMed PMID: 34026644; PubMed Central PMCID: PMC8138432.
   PubMed Web of Science ®Google Scholar
• Lin X, Lécuyer L, Liu X, et al. Plasma metabolomics for discovery of early metabolic markers of prostate cancer based on ultra-high-performance liquid chromatography-high resolution mass spectrometry. Cancers (Basel). 2021;13(13):3140. Epub 20210623. doi: 10.3390/cancers13133140 PubMed PMID: 34201735; PubMed Central PMCID: PMC8268247.
   PubMed Web of Science ®Google Scholar
• Li YF, Qiu S, Zhang AH. High-throughput metabolomics to identify metabolites to serve as diagnostic biomarkers of prostate cancer. Anal Methods. 2016;8(16):3284–3290. doi: 10.1039/c6ay00127k PubMed PMID: WOS:000374788500002.
   Web of Science ®Google Scholar
• Lin HM, Mahon KL, Weir JM, et al. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017;141(10):2112–2120. Epub 20170808. doi: 10.1002/ijc.30903 PubMed PMID: 28741687.
   PubMed Web of Science ®Google Scholar
• Lin HM, Huynh K, Kohli M, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):860–870. Epub 20210321. doi: 10.1038/s41391-021-00338-z PubMed PMID: 33746214; PubMed Central PMCID: PMC8387438.
   PubMed Web of Science ®Google Scholar
• Lima AR, Pinto J, Azevedo AI, et al. Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine. Br J Cancer. 2019;121(10):857–868. Epub 20191007. doi: 10.1038/s41416-019-0585-4 PubMed PMID: 31588123; PubMed Central PMCID: PMC6889512.
   PubMed Web of Science ®Google Scholar
• Gao Q, Su X, Annabi MH, et al. Application of urinary volatile organic compounds (VOCs) for the diagnosis of prostate cancer. Clin Genitourin Cancer. 2019;17(3):183–190. Epub 20190216. doi: 10.1016/j.clgc.2019.02.003 PubMed PMID: 30853355.
   PubMed Web of Science ®Google Scholar
• Lima AR, Pinto J, Barros-Silva D, et al. New findings on urinary prostate cancer metabolome through combined GC-MS and (1)H NMR analytical platforms. Metabolomics. 2020;16(6):70. Epub 20200603. doi: 10.1007/s11306-020-01691-1 PubMed PMID: 32495062.
   PubMed Web of Science ®Google Scholar
• Butler LM, Mah CY, Machiels J, et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Res. 2021;81(19):4981–4993. Epub 20210806. doi: 10.1158/0008-5472.can-20-3863 PubMed PMID: 34362796.
   PubMed Web of Science ®Google Scholar
• Li J, Ren S, Piao HL, et al. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. Sci Rep. 2016;6:20984. Epub 20160211. doi: 10.1038/srep20984 PubMed PMID: 26865432; PubMed Central PMCID: PMC4750101.
   PubMed Web of Science ®Google Scholar
• Li X, Nakayama K, Goto T, et al. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer. Cancer Sci. 2021;112(10):4292–4302. Epub 20210819. doi: 10.1111/cas.15093 PubMed PMID: 34328656; PubMed Central PMCID: PMC8486217.
   PubMed Web of Science ®Google Scholar
• Goto T, Terada N, Inoue T, et al. Decreased expression of lysophosphatidylcholine (16: 0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer. Prostate. 2015;75(16):1821–1830. Epub 20150901. doi: 10.1002/pros.23088 PubMed PMID: 26332786.
   PubMed Web of Science ®Google Scholar
• Knott ME, Manzi M, Zabalegui N, et al. Metabolic footprinting of a clear cell renal cell carcinoma in vitro model for human kidney cancer detection. J Proteome Res. 2018;17(11):3877–3888. Epub 20181012. doi: 10.1021/acs.jproteome.8b00538 PubMed PMID: 30260228.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang M, Sun H, et al. Urine metabolomics for renal cell carcinoma (RCC) prediction: tryptophan metabolism as an important pathway in RCC. Front Oncol. 2019;9:663. Epub 20190717. doi: 10.3389/fonc.2019.00663 PubMed PMID: 31380290; PubMed Central PMCID: PMC6653643.
   PubMed Web of Science ®Google Scholar
• Wu M, Li B, Zhang X, et al. Serum metabolomics reveals an innovative diagnostic model for salivary gland tumors. Anal Biochem. 2022;655:114853. doi: 10.1016/j.ab.2022.114853
   PubMed Web of Science ®Google Scholar
• Wood PL. Endogenous anti-inflammatory very-long-chain dicarboxylic acids: potential chemopreventive lipids. Metabolites. 2018;8(4):76. Epub 20181103. doi: 10.3390/metabo8040076 PubMed PMID: 30400281; PubMed Central PMCID: PMC6315409.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xu H, Liu R, et al. Highly sensitive quantification method for amine submetabolome based on AQC-Labeled-LC-Tandem-MS and multiple statistical data mining: a potential cancer screening approach. Anal Chem. 2018;90(20):11941–11948. Epub 20180928. doi: 10.1021/acs.analchem.8b02372 PubMed PMID: 30208276.
   PubMed Web of Science ®Google Scholar
• Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863–875. Epub 20170719. doi: 10.1016/j.tcb.2017.06.003 PubMed PMID: 28734735; PubMed Central PMCID: PMC5814137.
   PubMed Web of Science ®Google Scholar
• Wei D, Xu M, Wang Z, et al. The development of single-cell metabolism and its role in studying cancer emergent properties. Front Oncol. 2022;11:814085. doi: 10.3389/fonc.2021.814085
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang X, Liu H. Extracellular vesicles in cancer metabolism: implications for cancer diagnosis and treatment. Technol Cancer Res Treat. 2021;20:15330338211037821. doi: 10.1177/15330338211037821 PubMed PMID: 34427131; PubMed Central PMCID: PMC8388228.
   Web of Science ®Google Scholar
• Percival BC, Grootveld M, Gibson M, et al. Low-field, benchtop nmr spectroscopy as a potential tool for point-of-care diagnostics of metabolic conditions: validation, protocols and computational models. High Throughput. 2019;8(1):2. PubMed PMID: doi: 10.3390/ht8010002. doi: 10.3390/ht8010002
   Google Scholar
• Schmidt K, Podmore I. Current challenges in volatile organic compounds analysis as potential biomarkers of cancer. J Biomark. 2015;2015:1–16. Epub 20150330. doi: 10.1155/2015/981458 PubMed PMID: 26317039; PubMed Central PMCID: PMC4437398.
   Google Scholar